Kerckhoff-Klinik GmbH

At Kerckhoff-Klinik GmbH, a large share of the clinical research focuses on cardiovascular diseases, including acute coronary syndromes, heart failure, atrial fibrillation, and aortic stenosis. These studies are designed to test new treatment strategies, improve risk reduction, and strengthen care for people with complex heart conditions.

• Studying better ways to prevent recurrent myocardial infarction and other major cardiovascular events
• Evaluating therapies for heart failure, including reduced and preserved ejection fraction
• Assessing treatment approaches for atrial fibrillation and related stroke prevention
• Exploring interventions for aortic stenosis and post-procedure cardiac recovery

The work at this hospital-based research site supports both symptom control and long-term cardiovascular protection, with a strong emphasis on improving outcomes for high-risk patients.

Several trials at the site examine cardiac rhythm disorders and the prevention of clot-related complications, especially in people with persistent atrial fibrillation or atrial fibrillation after cardiac procedures. The overall aim is to refine treatment choices that reduce stroke risk while maintaining safety.

• Comparing approaches for early treatment of atrial fibrillation
• Investigating strategies to lower thromboembolic risk after catheter ablation or bypass surgery
• Testing whether stronger anticoagulation or antiplatelet approaches improve protection in selected patients
• Looking at better ways to manage acute coronary syndrome when rhythm problems are present

This research area combines cardiology and stroke prevention, aiming to improve everyday decision-making for patients with complex rhythm-related heart disease.

Another important focus is structural heart disease, including studies in hypertrophic cardiomyopathy, aortic stenosis, and myocardial remodeling after valve treatment. These trials often use advanced imaging to better understand how the heart changes over time and how treatment may improve function.

• Evaluating new therapies for symptomatic hypertrophic cardiomyopathy
• Assessing treatment effects on myocardial fibrosis and heart structure
• Exploring recovery after transcatheter aortic valve replacement
• Using cardiac magnetic resonance imaging to measure treatment response more precisely

These studies help clarify how structural heart conditions can be treated more effectively and how imaging can support more personalized care.

The site also conducts research in pulmonary hypertension and related heart-lung disorders, including cases linked to heart failure with preserved ejection fraction. The trials are intended to test whether new therapies can improve exercise capacity, symptoms, and overall disease burden.

• Studying treatment options for combined postcapillary and precapillary pulmonary hypertension
• Evaluating therapies for pulmonary hypertension associated with HFpEF
• Measuring changes in breathing capacity and physical performance
• Assessing both effectiveness and safety of emerging medicines

This area reflects a strong interest in difficult-to-treat conditions where the heart and lungs are closely connected.

Beyond cardiovascular medicine, Kerckhoff-Klinik GmbH is active in immune system diseases and inflammatory conditions such as giant cell arteritis, psoriatic arthritis, polymyositis, dermatomyositis, and systemic sclerosis-associated interstitial lung disease. These studies aim to improve control of inflammation and reduce disease relapses.

• Testing new therapies for autoimmune inflammation
• Reducing relapse risk in giant cell arteritis
• Improving symptoms and function in psoriatic arthritis and inflammatory muscle diseases
• Exploring treatment options for systemic sclerosis with lung involvement

These trials broaden the site’s research portfolio by addressing chronic inflammatory diseases that can seriously affect quality of life.